Cure My Disease

Don't miss your cure!

 Log in / Sign up

The real reason osteoporosis pills fail may be forgetfulness

NCT ID NCT07105163

Knowledge-focused Sponsor: Procare Health Iberia S.L. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 06, 2026 · Last updated Oct 07, 2026 · Updated 1 time

Summary

Researchers want to know how faithfully women with postmenopausal osteoporosis follow their prescribed treatment. The study enrolls 230 women who take an oral bisphosphonate pill weekly or monthly along with daily calcium and vitamin D supplements. At a single routine visit, participants answer three questionnaires about how often they take their medicine, whether they forget doses, and how satisfied they are with treatment. The goal is to compare adherence across different dosing schedules.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If researchers learn which pill schedules women stick with best, doctors could match osteoporosis treatment plans to the routines patients find easiest to follow.
What could go wrong
This study only asks women about their habits at one visit, so it cannot prove which schedule works better or whether better adherence prevents fractures. Answers may also be inaccurate if participants misremember.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

230 people

The number who actually took part.

Started

Mar 2025

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women with postmenopausal osteoporosis who have been prescribed treatment with an oral bisphosphonate combined with Ca/D supplements.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. \- Women diagnosed with postmenopausal OP. 2. \- Women who had been prescribed oral treatment with a BP administered monthly or weekly together with a Ca/D supplement (sachets or chewable tablets) administered daily, at least 6 months prior to inclusion in the study. 3. \- Women who had given their written informed consent before participating in the study. Exclusion Criteria: None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post menopausal osteoporosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postmenopausal osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post menopausal osteoporosis

Contacts and locations

Locations

  • CHU Insular - H Materno-Infantil

    Las Palmas de Gran Canaria, Canary Islands, Spain

  • CP Dr Agramonte

    Palma de Mallorca, Balearic Islands, Spain

  • CP Dr Balta

    Palma de Mallorca, Balearic Islands, Spain

  • CP Dr Caracuel

    Córdoba, Andalusia, Spain

  • CP Dr Larrauri

    Vigo, Pontevedra, Spain

  • CP Dr Solano

    Madrid, Madrid, Spain

  • CP Dr Zafra

    Madrid, Madrid, Spain

  • CP Dra Gerechter

    Madrid, Madrid, Spain

  • CP Dra Medrano

    Alicante, Valencia, Spain

  • CP Dra Sanchez

    Barcelona, Catalonia, Spain

  • CP Dra Tejon

    Alicante, Valencia, Spain

  • Clinica Gaias Santiago

    Santiago de Compostela, A coruña, Spain

  • Clinica Sagrada Familia

    Barcelona, Catalonia, Spain

  • Hospital Infanta Leonor

    Madrid, Madrid, Spain

  • Hospital Reina Sofia

    Córdoba, Andalusia, Spain

  • Hospital Virgen del Mar

    Madrid, Madrid, Spain

  • Hospital Virgen del Rocio

    Seville, Andalusia, Spain

  • Hospital Zamora

    Zamora, Castille and León, Spain

  • Hospital del Mar

    Barcelona, Catalonia, Spain

  • Hospital del Tajo

    Aranjuez, Madrid, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.